Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment

Chiang, Tsay-I; Chang, Ing‐Lin; Lee, H.-S.; Lee, H.; Huang, C.-H.; Cheng, Ya‐Wen

doi:10.1007/s00198-010-1327-x

Cited by 24 publications

(15 citation statements)

References 53 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pattern was unchanged in a multiple regression model. This seemed to be rational, since plasma OPN levels were considered to be a biomarker for early intermittent parathyroid hormone treatment response [21].…”

Section: Discussionmentioning

confidence: 99%

Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women

Wei

Huang

Tan

et al. 2015

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

Osteopontin (OPN) is an extracellular matrix protein that is expressed in bone cells such as osteoblast and osteocytes and associated with bone turnover and bone mineral density (BMD) in postmenopausal women. Here, we aimed to investigate the relationship between circulating OPN levels and BMD in postmenopausal women in Southern China. A total of 362 postmenopausal women were consecutively recruited into this study from 2011-2013. Serum levels of OPN, receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL), and bone turnover markers were analyzed. BMD was measured by dual energy X-ray absorptiometry. Osteoporosis and osteopenia were diagnosed according to the World Health Organization criteria. Serum OPN levels were remarkably higher in the osteoporotic group than those in the osteopenic and normal groups (all p < 0.001). The cut-off value of OPN for diagnosing postmenopausal osteoporosis was 10.1 ng/mL, which had a sensitivity of 89.5%, a specificity of 70.8%, and an area under curve of 0.953. Serum OPN was negatively correlated with parathyroid hormone (PTH), lumbar spine BMD, and femoral neck BMD (r = -0.25, p = 0.004; r = -0.66, p < 0.001; r = -0.28, p = 0.001; respectively) and positively associated with type I procollagen amino-terminal propeptide (PINP), carboxy-terminal cross-linking telopeptide of type I collagen (CTX), and RANKL (r = 0.20, p = 0.020; r = 0.17, p = 0.036; r = 0.19, p = 0.028, respectively) in the osteoporotic group. In multiple regression analyses, lumbar spine BMD, PTH and RANKL were the predictors for serum OPN levels. In conclusion, OPN serum levels are negatively related to BMD and positively correlated with bone turnover levels in this group of Chinese postmenopausal women.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women

Wei

Huang

Tan

et al. 2015

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…Recent study shows that women with OP over-expression reveal less resistance to postmenopausal osteoporosis than women with normal OP levels [54]. The levels of plasma OP could be used as a biomarker to evaluate the treatment of intermittent parathyroid hormone in menopausal osteoporosis.…”

Section: Bone Resorption Biomarkersmentioning

confidence: 99%

Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives

2017

View full text Add to dashboard Cite

Bone biomarkers included formation, resorption and regulator are released during the bone remodeling processes. These bone biomarkers have attracted much attention in the clinical assessment of osteoporosis treatment in the past decade. Combination with the measurement of bone mineral density, the clinical applications of bone biomarkers have provided comprehensive information for diagnosis of osteoporosis. However, the analytical approaches of the bone biomarkers are still the challenge for further clinical trials. In this mini-review, we have introduced the functions of bone biomarkers and then recently developed techniques for bone biomarker measurements have been systematically integrated to discuss the possibility for osteoporosis assessment in the early stage.

show abstract

“…17 Osteopontin levels were related to the anabolic effect of parathyroid hormone, suggesting that OPN might be used as a biomarker for early treatment response. 18 …”

mentioning

confidence: 99%

The Value of Osteopontin in the Assessment of Bone Mineral Density Status in Postmenopausal Women

Fodor

Bondor

Albu

et al. 2013

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment

Abstract: OPN levels are related to the anabolic effect of PTH in human postmenopausal osteoporosis. Plasma OPN levels could be used as a biomarker for early treatment response.

Cited by 24 publications

References 53 publications

Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women

Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women

Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives

The Value of Osteopontin in the Assessment of Bone Mineral Density Status in Postmenopausal Women

Contact Info

Product

Resources

About